News|Articles|February 19, 2026

From Launch to Loss of Exclusivity: Reducing Access and Affordability Barriers Across the Brand Lifecycle

Author(s)CoverMyMeds

Access and affordability challenges continue to evolve across every phase of the biopharma brand lifecycle. Megan Wetzel, Vice President of Product, Access & Affordability at CoverMyMeds, shares actionable, lifecycle-specific approaches to removing barriers, easing provider burden, and supporting patient adherence. These strategies offer guidance for strengthening brand performance from launch through maturity while improving patient outcomes.

What you’ll learn:

  1. Discover how access barriers evolve across the biopharma brand lifecycle, from launch to loss of exclusivity, and how to address them proactively.
  2. Learn how data-driven insights and affordability solutions can help biopharma support providers and pharmacists at every stage.
  3. Understand the strategic role of lifecycle planning in improving medication access, reducing industry fragmentation and enhancing patient outcomes.

DOWNLOAD Q&A


Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.